Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Outsourcing services are on of the pillars of Merck's business, delivered via its process solutions unit, part of the group's life sciences division. The unit contributed almost €3.4 billion out ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for $600 million, it said ahead of its Capital ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced.

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

The Merck Future Insight prize was established ... Dream products must be something that cannot be realized with an established science or technology but should be reachable within the next ...

About the Life Science business of Merck KGaA, Darmstadt ... by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please ...